Document is current
Any future updates will be listed below
-
Authors
Zhong, Yiye
Le, Huangying
Zhang, Xue
Dai, Yao
Guo, Fang
Ran, Xiaojuan
Hu, Guohong
Xie, Qi
Wang, Dawei
Cai, Yujia
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82003781, 31971364)
Yangfan project from the Science and Technology Commission of Shanghai Municipality (20YF1421900)
Start-up Fund by Shanghai Jiao Tong University (20X100040058)
Guangci Distinguished Young Scholars Training Program (GCQN-2019-B17)
Key-research Fund from State Key Laboratory of Medical Genomics (2022-13-2)
Fundamental Research Funds for the Central Universities (YG2024QNB02)
National Key Research and Development Program of China (2022YFC3400205)
Science and Technology Innovation Action Plan of Shanghai (24Z510200306)
Key Forward-Looking Fund from Shanghai Jiao Tong University (AF4150049)
- License Information
-
More Information
Article History
Received: 30 January 2024
Accepted: 6 May 2024
First Online: 23 May 2024
Declarations
:
: All animal-related experiments were performed under the guidelines of the Institutional Animal Care and Use Committee (IACUC) of the Shanghai Jiao Tong University with approval from the Animal Ethics Committee. When the tumor size reaches 1500 mm<sup>3</sup>, the animals were euthanized. The maximal tumoral size did not exceed 1500 mm<sup>3</sup>.
: Not applicable.
: Y.C. is a co-founder and advisor of BDGENE Therapeutics. The other authors declare no competing interests. Y.C. filed a patent application (CN202111233544.9) related to this work.
